ANTI DOG CD3:FITC/CD4:RPE/CD8:Alexa Fluor® 647 from Bio-Rad (AbD Serotec - FAB)

Yes, the ANTI DOG CD3:FITC/CD4:RPE/CD8:Alexa Fluor® 647 has been utilized in studies to analyze T lymphocyte populations in dogs. For instance, it was employed in a study examining the immune response in dogs with myxomatous mitral valve disease, where it helped in identifying various T cell subsets, including CD4 and CD8 T lymphocytes, through flow cytometry (cimerman2024).

The antibody combination has been shown to be effective for immunophenotyping in canine cancer research. In a study on dogs with oral melanoma, it was used to assess the frequency of blood lymphocyte subsets, including CD4 and CD8 T lymphocytes, which are critical for evaluating immune responses to treatments (garcia2022).

This product targets CD3, CD4, and CD8 markers, which are essential for identifying different T cell populations. These markers are relevant in veterinary medicine for understanding immune responses in various conditions, such as heart disease and cancer, as they provide insights into the status of the immune system in dogs (guzera2016; stokol2024).

Yes, there are multiple studies that have cited the use of this antibody combination in clinical settings. For example, it was referenced in research investigating the association of immune indices with survival in dogs with myxomatous mitral valve disease and in studies assessing immune responses in canine patients with oral melanoma (cimerman2024; garcia2022).